表紙
市場調查報告書
商品編碼
1000852

傷寒(傳染病):藥物開發中,2021年

Typhoid Fever (Infectious Disease) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 57 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

傷寒是一種傳染性疾病,會引起腹瀉和皮疹。最常見的原因是一種稱為傷寒的細菌。主要症狀包括壓痛,躁動,發冷,del妄,幻覺,嚴重不適和腹部無力。主要治療方法包括抗生素和支持治療。

本報告分析了全球用於治療傷寒的管道產品的發展狀況,產品開發和發佈的最新趨勢,臨床試驗各個階段的產品清單,主要公司的概況以及主要的我們將為您提供信息,例如各種藥物的概述和最新的行業趨勢。

目錄

  • 簡介
  • 分析範圍
  • 傷寒:概述
  • 傷寒:治療藥物的開發
  • 管道產品概述
  • 管道產品:按公司分類
  • 管道產品:按大學/研究所分類
  • 每個公司正在開發的產品
  • 每所大學/研究機構正在開發的產品
  • 傷寒:治療藥物的評估
  • 按目標評估
  • 按管理途徑評估
  • 按分子類型評估
  • 傷寒:從事治療藥物開發的公司
  • Enesi Pharma Ltd
  • Etna Biotech Srl
  • Eubiologics Co Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Matrivax Research & Development Corp
  • Novo Medi Sciences Pvt Ltd
  • Prokarium Ltd
  • Protein Potential LLC
  • Sanofi Pasteur SA
  • Shantha Biotechnics Pvt Ltd
  • Walvax Biotechnology Co Ltd
  • 傷寒:藥物資料
  • (傷寒(二價)+傷寒)疫苗:藥物概況
  • 產品概述
  • 作用機理(MoA)
  • 研發進展(研發)
  • (副傷寒+傷寒)疫苗:藥物檔案
  • (輪狀病毒(病毒樣顆粒)+傷寒疫苗)疫苗:藥物概況
  • (志賀氏菌+傷寒)(二價)疫苗:藥物概況
  • (鏈球菌性肺炎+傷寒)疫苗:藥物概況
  • EUC-002:藥物資料
  • 傳染病疫苗:藥物資料
  • typhax:藥物概況
  • 傷寒:藥物概況
  • 傷寒疫苗:藥物概況
  • 傷寒疫苗:藥物概況
  • 傷寒疫苗:藥物概況
  • 傷寒疫苗:藥物概況
  • 傷寒疫苗:藥物概況
  • 傷寒疫苗:藥物概況
  • 傷寒疫苗:藥物概況
  • 傷寒Vi多醣[StyphiTy2株]疫苗:藥物概況
  • ViCRM-197:藥物資料
  • 傷寒:發展處於休眠狀態的項目
  • 傷寒:已停止開發的產品
  • 傷寒:產品開發里程碑
  • 主要新聞和新聞發佈
  • 附錄
目錄
Product Code: GMDHC12799IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Typhoid Fever - Drugs in Development, 2021, provides an overview of the Typhoid Fever (Infectious Disease) pipeline landscape.

Typhoid fever is an infection that causes diarrhea and a rash. It is most commonly due to a type of bacterium called Salmonella typhi (S. typhi). Symptoms include abdominal tenderness, agitation, chills, delirium, hallucinations, severe fatigue and weakness. Treatment includes antibiotics and supportive therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Typhoid Fever - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Typhoid Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Typhoid Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Typhoid Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 2, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Unknown stages comprises 1, 2 and 1 molecules, respectively.

Typhoid Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Typhoid Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Typhoid Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Typhoid Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Typhoid Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Typhoid Fever (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Typhoid Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Typhoid Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Typhoid Fever - Overview
  • Typhoid Fever - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Typhoid Fever - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Typhoid Fever - Companies Involved in Therapeutics Development
  • Enesi Pharma Ltd
  • Etna Biotech Srl
  • Eubiologics Co Ltd
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Matrivax Research & Development Corp
  • Novo Medi Sciences Pvt Ltd
  • Prokarium Ltd
  • Protein Potential LLC
  • Sanofi Pasteur SA
  • Shantha Biotechnics Pvt Ltd
  • Walvax Biotechnology Co Ltd
  • Typhoid Fever - Drug Profiles
  • (paratyphoid (bivalent) + typhoid) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (paratyphoid + typhoid) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (rotavirus (virus like particle) + typhiod) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (shigella + typhoid) (Bivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (Streptococcal pneumonia + typhoid) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EUC-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • infectious disease vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Typhax - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Typhella - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • typhoid vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • typhoid vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • typhoid vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • typhoid vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • typhoid vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • typhoid vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • typhoid vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • typhoid Vi polysaccharide [strain S typhi Ty2] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ViCRM-197 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Typhoid Fever - Dormant Projects
  • Typhoid Fever - Discontinued Products
  • Typhoid Fever - Product Development Milestones
  • Featured News & Press Releases
  • Dec 17, 2020: IVI-SK's new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal
  • Sep 17, 2020: Typhoid: Study confirms Vi-DT conjugate vaccine is safe and immunogenic in children 6-23 months of age
  • Jul 14, 2020: Prokarium obtains notice of allowance for US patent covering the modification of an attenuated strain of salmonella enterica serovar typhi to develop a vaccine against enteric fever
  • Nov 26, 2019: Prokarium announces MHRA acceptance to run phase i trial of lead vaccine against enteric fever
  • Oct 08, 2019: Prokarium secures £4.6M from Wellcome to fund the clinical development of its lead vaccine programme
  • Oct 08, 2012: Typhim Vi - Typhoid Polysaccharide Vaccine - antigen levels below required specification
  • Oct 05, 2012: Sanofi Pasteur Voluntarily Recalls Few Batches Of Typhoid Fever Vaccine
  • Jun 23, 2011: Sanofi Pasteur's Typhim Vi Receives Prequalification From World Health Organization
  • Jun 05, 2008: Emergent BioSolutions Initiates U.S. Phase II Trial of Oral Typhoid Vaccine Candidate
  • Jan 08, 2008: Emergent BioSolutions Announces Final Phase II Clinical Study Results for Typhoid Vaccine
  • Nov 21, 2005: Emergent Biosolutions Starts Clinical Study Of Single-Dose Oral Typhoid Vaccine
  • Aug 30, 2005: Emergent Biosolutions' Typhoid Vaccine Achieves Positive Results In Phase II Clinical Study
  • Nov 29, 1994: Food And Drug Administration Grants License For A New Typhoid Fever Vaccine
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Typhoid Fever, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Typhoid Fever - Pipeline by Enesi Pharma Ltd, 2021
  • Typhoid Fever - Pipeline by Etna Biotech Srl, 2021
  • Typhoid Fever - Pipeline by Eubiologics Co Ltd, 2021
  • Typhoid Fever - Pipeline by GlaxoSmithKline Plc, 2021
  • Typhoid Fever - Pipeline by Indian Immunologicals Ltd, 2021
  • Typhoid Fever - Pipeline by Matrivax Research & Development Corp, 2021
  • Typhoid Fever - Pipeline by Novo Medi Sciences Pvt Ltd, 2021
  • Typhoid Fever - Pipeline by Prokarium Ltd, 2021
  • Typhoid Fever - Pipeline by Protein Potential LLC, 2021
  • Typhoid Fever - Pipeline by Sanofi Pasteur SA, 2021
  • Typhoid Fever - Pipeline by Shantha Biotechnics Pvt Ltd, 2021
  • Typhoid Fever - Pipeline by Walvax Biotechnology Co Ltd, 2021
  • Typhoid Fever - Dormant Projects, 2021
  • Typhoid Fever - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Typhoid Fever, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021